• Home
  • Media
  • Press Releases
  • Julphar takes part in Duphat 2022 consolidating its role in the regional and global healthcare sector.

Julphar takes part in Duphat 2022 consolidating its role in the regional and global healthcare sector.


Gulf Pharmaceutical Industries Julphar, one of the leading pharmaceutical manufacturers in the Middle East and Africa, participates in the 27th edition of the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT 2022), the event that takes place in the Dubai International Convention & Exhibition Centre from 22-25 February 2022, inaugurated by His Highness Sheikh Ahmed bin Mohammed bin Rashid Al Maktoum, Chairman of the Dubai Media Council.


Julphar, the UAE leading pharmaceutical brand, is a significant partner in the Dubai International Pharmaceuticals and Technologies Conference and Exhibition (Duphat) 2022, kick-starting this week in Dubai. DUPHAT 2022 provides an opportunity to update various Pharma stakeholders on the latest trends and relevant technologies that can optimize the industry practice, strategies, and research quality. Prominent figures and experts worldwide will enrich the conference and exhibition with their experiences and achievements in the Pharma field.


Commenting on Julphar participation in DUPHAT 2022, Mr. Ahmed Al Khatib, Director of Corporate PR and Communications at Julphar, said: “Over the past three decades, Julphar has transitioned from a local UAE company to a truly global player, distributing its products to more than 35 countries across the globe and leading efforts in the region to enhance access to quality healthcare by producing safe and affordable medicines.”


“DUPHAT has always been a platform that focuses on addressing the region’s pharmaceutical sector by providing a unique opportunity for companies to launch new products, learn about new technologies and developments, acquire scientific knowledge, network with industry peers, exchange expertise and experiences with specialists, and explore solutions to resolve challenges in the industry.”


Mohammed Ibrahim, GCC Director at Julphar, said: "As an Emirati pharmaceutical company, we uniquely positioned to strengthen the biotechnology capabilities and provide the much-increasing requirement to support diabetes and cardiovascular portfolios with long-acting insulin analogs, e.g., Insulin Glargine and similar analogs. By investing in innovation, we have created several breakthroughs in healthcare. These include being recognized as one of the world's largest producers of insulin that our state-of-the-art UAE-based biotechnology facility supports.


"Julphar manages a diverse portfolio of therapeutic products, covering a wide range of major pharmaceutical segments, including consumer, endocrinology, antibiotics, cardiovascular, women's health, dermatology, gastroenterology, metabolic, nephrology, wound and scar, and respiratory. He added.


The Dubai Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT) is the most significant pharmaceutical show in the MENA region. The three-day event attracts the world's leading pharmacists, marketing personnel, researchers, academics, scientists, clinicians, students, and other healthcare professionals, all under one roof. Dubai is the ideal hub for this conference, given the UAE's heavy investment in the pharmaceutical industry.

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, refer to our Cookie Policy.